Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses

Drug Discovery Today

Volumn 12, Issue 15-16, 2007, Pages 674-681

  Barbosa, Maria D F S ^a   Celis, Esteban ^b  

^a CA Consultants   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADECATUMUMAB; ALPHA INTERFERON; ANTIBODY; BETA INTERFERON; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8; CANCER VACCINE; CD4 ANTIGEN; DIPHTHERIA VACCINE; EDRECOLOMAB; EPITOPE; ERYTHROPOIETIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; TETANUS TOXOID; THROMBOPOIETIN; VACCINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HELPER CELL; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW;

ANIMALS; ANTIBODY FORMATION; DRUG DESIGN; DRUG INDUSTRY; HUMANS; IMMUNE TOLERANCE; MODELS, THEORETICAL; RECOMBINANT PROTEINS;

EID: 34547743906     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.06.005     Document Type: Review

References (109)

1. Pedotti R., et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2 (2001) 216-222
2. Rosenberg A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112 (2003) 15-21
3. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J. 8 (2006) E501-E507
4. Kuter D.J., and Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100 (2002) 3457-3469
5. Carson K.R., et al. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract. Res. Clin. Haematol. 18 (2005) 467-472
6. Li J., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
7. Evens A.M., et al. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract. Res. Clin. Haematol. 18 (2005) 481-489
8. Bertolotto A., et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95-100
9. Korner J., and Aronne L.J. Pharmacological approaches to weight reduction: therapeutic targets. J. Clin. Endocrinol. Metab 89 (2004) 2616-2621
10. Steinman R.M. The control of immunity and tolerance by dendritic cell. Pathol. Biol. (Paris) 51 (2003) 59-60
11. Chin L.T., et al. Mimicking the humoral immune response in vitro results in antigen-specific isotype switching supported by specific autologous T helper cells: generation of human HIV-1-neutralizing IgG monoclonal antibodies from naive donors. Eur. J. Immunol. 25 (1995) 657-663
12. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
13. Barbosa M.D., et al. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118 (2006) 42-50
14. Mire-Sluis A.R., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289 (2004) 1-16
15. Gupta S., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321 (2007) 1-18
16. Nicod L.P., et al. Antigen presentation in the lung: dendritic cells and macrophages. Sarcoidosis. Vasc. Diffuse Lung Dis. 17 (2000) 246-255
17. Brandes M., et al. Professional antigen-presentation function by human gammadelta T Cells. Science 309 (2005) 264-268
18. Chung J.B., et al. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness. J. Immunol. 171 (2003) 1758-1767
19. Crawford A., et al. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176 (2006) 3498-3506
20. Quaratino S., et al. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10911-10916
21. Kleindienst P., and Brocker T. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo. Immunology 115 (2005) 556-564
22. Boes M., et al. Membrane specializations and endosome maturation in dendritic cells and B cells. Trends Cell Biol. 14 (2004) 175-183
23. Corthay A. A three-cell model for activation of naive T helper cells. Scand J. Immunol. 64 (2006) 93-96
24. Dooms H., and Abbas A.K. Control of CD4+ T-cell memory by cytokines and costimulators. Immunol. Rev. 211 (2006) 23-38
25. Martin F., et al. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14 (2001) 617-629
26. Gray D., et al. CD40 ligation in B cell activation, isotype switching and memory development. Semin Immunol. 6 (1994) 303-310
27. Chirino A.J., et al. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9 (2004) 82-90
28. De Groot A.S. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov. Today 11 (2006) 203-209
29. Stickler M., et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immunol. 5 (2004) 1-7
30. Yeung V.P., et al. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172 (2004) 6658-6665
31. Tangri S., et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174 (2005) 3187-3196
32. Inaba H., et al. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J. Clin. Endocrinol. Metab 91 (2006) 2286-2294
33. Warren K.G., et al. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152 (1997) 31-38
34. Goebels N., et al. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 Pt. 3 (2000) 508-518
35. Tuohy V.K., et al. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J. Autoimmun. 13 (1999) 11-20
36. Ettinger R.A., and Kwok W.W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J. Immunol. 160 (1998) 2365-2373
37. Squire I.B., et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur. Heart J. 20 (1999) 1245-1252
38. Kuus-Reichel K., et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin. Diagn. Lab. Immunol. 1 (1994) 365-372
39. Saleh M.N., et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol. Immunother. 32 (1990) 185-190
40. Oberneder R., et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur. J. Cancer 42 (2006) 2530-2538
41. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'?. Immunol. Today 21 (2000) 397-402
42. Vanderlugt C.L., et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol. Rev. 164 (1998) 63-72
43. Klehmet J., et al. T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. Clin. Immunol. 111 (2004) 53-60
44. McMahon E.J., et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11 (2005) 335-339
45. Disis M.L., et al. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 24 (2004) 571-578
46. Chen L., et al. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. 17 (2006) 3076-3081
47. Rosmalen J.G., et al. T-cell education in autoimmune diabetes: teachers and students. Trends Immunol. 23 (2002) 40-46
48. Sun J., et al. Cell cycle block in anergic T cells during tolerance induction. Cell Immunol. 225 (2003) 33-41
49. Goldschneider I., and Cone R.E. A central role for peripheral dendritic cells in the induction of acquired thymic tolerance. Trends Immunol. 24 (2003) 77-81
50. Chen M., et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 311 (2006) 1160-1164
51. Rup B. Immunogenicity and immune tolerance coagulation Factors VIII and IX. Dev. Biol. (Basel) 112 (2003) 55-59
52. Ho A.Y., et al. Immune tolerance therapy for haemophilia. Drugs 60 (2000) 547-554
53. Graca L., and Waldmann H. Reprogramming the immune system using antibodies. Methods Mol. Biol. 333 (2006) 247-268
54. Waldmann H., and Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today 14 (1993) 247-251
55. Hay C.R., et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb. Haemost. 77 (1997) 234-237
56. Goodeve A.C., et al. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb. Haemost. 83 (2000) 844-848
57. Hermeling S., et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22 (2005) 1997-2006
58. Hermeling S., et al. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm Sci. 95 (2006) 1084-1096
59. Purohit V.S., et al. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J. Pharm. Sci. 95 (2006) 358-371
60. Maas C., et al. A role for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol. Chem. (2006)
61. Chirino A.J., and Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 22 (2004) 1383-1391
62. Bertolotto A., et al. Immunogenicity of interferon beta: differences among products. J. Neurol. 251 Suppl. 2 (2004) II15-II24
63. Braun A., et al. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14 (1997) 1472-1478
64. Sturniolo T., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17 (1999) 555-561
65. Kwok W.W., et al. Use of class II tetramers for identification of CD4+ T cells. J. Immunol. Methods 268 (2002) 71-81
66. Stone J.D., et al. HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and co-stimulatory microarrays. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3744-3749
67. Rohn T.A., et al. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res. 65 (2005) 10068-10078
68. Bui H.H., et al. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 246-251
69. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001) 1236-1237
70. Busch R., et al. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int. Immunol. 2 (1990) 443-451
71. Dedier S., et al. Use of fluorescence polarization to monitor MHC-peptide interactions in solution. J. Immunol. Methods 255 (2001) 57-66
72. Jennes W., et al. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. J. Immunol. Methods 270 (2002) 99-108
73. Nguyen X.D., et al. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J. Immunol. Methods 275 (2003) 57-68
74. De Boer R.J., et al. Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol. 68 (2006) 1011-1031
75. Maghni K., et al. Suitability of cell metabolic colorimetric assays for assessment of CD4+ T cell proliferation: comparison to 5-bromo-2-deoxyuridine (BrdU) ELISA. J. Immunol. Methods 223 (1999) 185-194
76. Lofgren J.A., et al. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods 308 (2006) 101-108
77. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J. Interferon. Cytokine Res. 17 Suppl. 1 (1997) S15-S21
78. Jones T.D., et al. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J. Interferon. Cytokine Res. 24 (2004) 560-572
79. Rossert J., et al. Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. 15 (2004) 398-406
80. Jacquemin M., et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101 (2003) 1351-1358
81. Young G., et al. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 11 (2005) 203-207
82. Jones T.D., et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb Haemost. 3 (2005) 991-1000
83. Pratt K.P., et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb. Haemost. 92 (2004) 522-528
84. Olerup O., and Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38 (1991) 1-15
85. Ota K., et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
86. Warren K.G., et al. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11061-11065
87. Vergelli M., et al. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J. Neuroimmunol. 77 (1997) 195-203
88. Mukku P.V., et al. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2. Mol. Immunol. 32 (1995) 555-564
89. Valli A., et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest 91 (1993) 616-628
90. Noble J.A., et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am. J. Hum. Genet 59 (1996) 1134-1148
91. Todd J.A., et al. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
92. Petersen J.S., et al. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43 (1994) 459-467
93. Ronkainen M.S., et al. Antibodies to GAD65 epitopes at diagnosis and over the first 10 years of clinical type 1 diabetes mellitus. Scand J. Immunol. 59 (2004) 334-340
94. Hawa M.I., et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diab. Care 23 (2000) 228-233
95. Hall T.R., et al. Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes. Clin. Exp. Immunol. 146 (2006) 9-14
96. Nakayama M., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (2005) 220-223
97. Harfouch-Hammoud E., et al. Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes 48 (1999) 1937-1947
98. Abiru N., et al. Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse. J. Autoimmun. 14 (2000) 231-237
99. Reijonen H., et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 53 (2004) 1987-1994
100. Kent S.C., et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 (2005) 224-228
101. Zanelli E., et al. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum. Immunol. 61 (2000) 1254-1261
102. Wordsworth B.P., et al. Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10. Br. J. Rheumatol. 30 (1991) 178-180
103. MacGregor A., et al. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J. Rheumatol. 22 (1995) 1032-1036
104. Hill J.A., et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171 (2003) 538-541
105. Taneja V., and David C.S. Association of MHC and rheumatoid arthritis. Regulatory role of HLA class II molecules in animal models of RA: studies on transgenic/knockout mice. Arthritis Res. 2 (2000) 205-207
106. Penzotti J.E., et al. A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis. J. Autoimmun. 9 (1996) 287-293
107. Allannic H., et al. HLA and Graves' disease: an association with HLA-DRw3. J. Clin. Endocrinol. Metab. 51 (1980) 863-867
108. Barlow A.B., et al. Association of HLA-DQA1*0501 with Graves' disease in English Caucasian men and women. Clin. Endocrinol. (Oxf.) 44 (1996) 73-77
109. Akamizu T., et al. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology 140 (1999) 1594-1601